Evaxion approaches crossroads in gonorrhea vaccine development
After a prominent US research institute decided to aid further development of the Danish biotech firm’s gonorrhea candidate, next steps are being mulled over. Should Evaxion out-license its vaccine, or continue on public funding?
by albert rønning-andersson, translated by daniel pedersen
Evaxion Biotech said in June that gonorrhea had been chosen as the target for the company’s vaccine candidate, EVX-B2.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
